# CytomX Therapeutics (CTMX) — Analyst Forecast

CTMX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/ctmx/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 8 | 0 | 0 | 8 |

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Aug 13, 2026 | JP Morgan | Maintained | Overweight | $11.00 |
| Aug 10, 2026 | Guggenheim | Maintained | Buy | $14.00 |
| May 11, 2026 | HC Wainwright & Co. | Maintained | Buy | $11.00 |
| Mar 23, 2026 | Piper Sandler | Maintained | Overweight | $12.00 |
| Mar 19, 2026 | Barclays | Maintained | Overweight | $16.00 |
| Mar 18, 2026 | Guggenheim | Maintained | Buy | $15.00 |
| Mar 18, 2026 | Jefferies | Maintained | Buy | $16.00 |
| Mar 17, 2026 | Wedbush | Maintained | Outperform | $11.00 |
| Mar 16, 2026 | JP Morgan | Upgraded | Neutral → Overweight | $12.00 |
| Mar 16, 2026 | HC Wainwright & Co. | Maintained | Buy | $17.00 |
| Mar 9, 2026 | Guggenheim | Maintained | Buy | $10.00 |
| Feb 4, 2026 | Barclays | Maintained | Overweight | $10.00 |
| Feb 4, 2026 | Cantor Fitzgerald | Maintained | Overweight | $10.00 |
| Jan 20, 2026 | Piper Sandler | Maintained | Overweight | $10.00 |
| Jan 20, 2026 | Barclays | Maintained | Overweight | $8.00 |
| Jan 20, 2026 | Guggenheim | Initiated Coverage | Buy | $10.00 |
| Nov 11, 2025 | HC Wainwright & Co. | Maintained | Buy | $10.00 |
| Oct 21, 2025 | Barclays | Maintained | Overweight | $6.00 |
| Sep 22, 2025 | Cantor Fitzgerald | Initiated Coverage | Overweight | $6.00 |
| Sep 17, 2025 | Barclays | Initiated Coverage | Overweight | $3.50 |

## Frequently Asked Questions

### Is CTMX a buy, sell, or hold?

Analysts covering CytomX Therapeutics currently average a Buy rating: 8 buy, 0 hold and 0 sell, from 8 analysts. Ratings reflect analyst opinion, not investment advice.

### What is the latest analyst rating on CTMX?

On Aug 13, 2026, JP Morgan maintained CytomX Therapeutics at Overweight with a price target of $11.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).